Strategic Partnerships Alamar's recent collaborations with major research institutions (University of Wisconsin, Washington University in St. Louis, Indiana University) and planned integration with Frontage Laboratories signal a strong channel strategy and potential co-selling opportunities for expanding access to NULISAseq panels and ARGO systems.

IBC Expansion The company is actively expanding into in vitro diagnostic development using ALZpath and Alzheimer’s blood testing, presenting a cross-sell opportunity to offer NULISAseq Neuro panels alongside diagnostic assays to target neurology-focused clinics and labs.

PE Growth Robust revenue growth with Q2 2026 revenue of $29.4M and a year-over-year increase, coupled with a successful IPO, suggests capacity to scale pilots into larger enterprise deployments for proteomics workflows, consumables, and service contracts.

Global Outreach Participation in prestigious investor conferences and a global service network position Alamar to pursue international lab partnerships and instrument placements, expanding market reach for automation-intensive, high-sensitivity assays.

Product Differentiation NULISA chemistry enabling ultra-high sensitivity with automated, low hands-on time and dual readouts (qPCR and NGS) provides a competitive edge for multiplex biomarker panels; leverage this to upsell to customers seeking faster, scalable proteomics solutions and high dynamic range assays.